Qube Research & Technologies (QRT)
CTMX icon

Qube Research & Technologies (QRT)’s CytomX Therapeutics CTMX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.4M Buy
4,187,989
+2,363,425
+130% +$7.88M 0.01% 1365
2026
Q2 		$6.84M Sell
1,824,564
-425,019
-19% -$1.62M 0.01% 1476
2026
Q1 		$10.6M Buy
2,249,583
+1,188,455
+112% +$6.03M 0.01% 1246
2025
Q4 		$4.52M Buy
1,061,128
+938,628
+766% +$3.57M ﹤0.01% 1823
2025
Q3 		$391K Buy
+122,500
New +$276K ﹤0.01% 2771
2025
Q2 		– Sell
-54,808
Closed -$34.8K – 3601
2025
Q1 		$34.8K Sell
54,808
-300
-0.5% -$233 ﹤0.01% 3168
2024
Q4 		$56.8K Hold
55,108
– – ﹤0.01% 3083
2024
Q3 		$65K Buy
55,108
+500
+0.9% +$635 ﹤0.01% 2814
2024
Q2 		$66.6K Sell
54,608
-78,591
-59% -$156K ﹤0.01% 2681
2024
Q1 		$290K Buy
133,199
+132,940
+51,328% +$245K ﹤0.01% 2837
2023
Q4 		$401 Hold
259
– – ﹤0.01% 3932
2023
Q3 		$334 Buy
+259
New +$408 ﹤0.01% 3710
2023
Q2 		– Sell
-13,050
Closed -$19.7K – 2487
2023
Q1 		$19.7K Sell
13,050
-43,231
-77% -$97.7K ﹤0.01% 2313
2022
Q4 		$90K Buy
56,281
+5,695
+11% +$8.43K ﹤0.01% 2028
2022
Q3 		$73K Sell
50,586
-5,260
-9% -$8.1K ﹤0.01% 2058
2022
Q2 		$102K Buy
+55,846
New +$107K ﹤0.01% 1945
2021
Q3 		– Sell
-18,101
Closed -$115K – 2301
2021
Q2 		$115K Buy
+18,101
New +$141K ﹤0.01% 1923

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CTMX Position: Q3 2026 in Review

Qube Research & Technologies (QRT) increased its CytomX Therapeutics (CTMX) stake by 130% in Q3 2026, buying an estimated $7.88M and bringing the position to 4,187,989 shares worth $11.4M. The position accounts for 0.01% of the portfolio, ranked #1365.

Qube Research & Technologies (QRT) first reported a position in CTMX in Q2 2021 and has held it in 17 quarters since. 128 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Qube Research & Technologies (QRT) held 4,187,989 shares of CytomX Therapeutics worth $11.4M as of Q3 2026.
  • Qube Research & Technologies (QRT) bought 2,363,425 CytomX Therapeutics shares in Q3 2026, an estimated $7.88M.
  • CytomX Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #1365 holding.
  • Qube Research & Technologies (QRT) first reported a position in CytomX Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • 128 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.